These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 698402)

  • 1. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII.
    Seligsohn U; Osterud B; Rapaport SI
    Blood; 1978 Nov; 52(5):978-88. PubMed ID: 698402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of human factor VII during clotting in vitro.
    Rao LV; Bajaj SP; Rapaport SI
    Blood; 1985 Jan; 65(1):218-26. PubMed ID: 3871163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to measure factor VII and factor VII activation.
    Osterud B
    Haemostasis; 1983; 13(3):161-8. PubMed ID: 6350121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment.
    Avvisati G; ten Cate JW; van Wijk EM; Kahlé LH; Mariani G
    Br J Haematol; 1980 Jun; 45(2):343-52. PubMed ID: 7437329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study.
    Miller GJ; Stirling Y; Esnouf MP; Heinrich J; van de Loo J; Kienast J; Wu KK; Morrissey JH; Meade TW; Martin JC
    Thromb Haemost; 1994 Jan; 71(1):38-48. PubMed ID: 8165645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An association between the factor VII coagulant activity and thrombin activity induced by surface/cold exposure of normal human plasma.
    Miller GJ; Seghatchian MJ; Walter SJ; Howarth DJ; Thompson SG; Esnouf MP; Meade TW
    Br J Haematol; 1986 Feb; 62(2):379-84. PubMed ID: 3484967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.
    Poller L; Thomson JM; Bodzenta A; Easton AC; Latallo ZS; Chmielewska J
    Br J Haematol; 1981 Sep; 49(1):69-75. PubMed ID: 7272230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa.
    Bajaj SP; Rapaport SI; Brown SF
    J Biol Chem; 1981 Jan; 256(1):253-9. PubMed ID: 6778860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
    van Dieijen-Visser MP; van Wersch J; Brombacher PJ; Rosing J; Hemker HC; van Dieijen G
    Haemostasis; 1982; 12(3):241-55. PubMed ID: 7141303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VII activation and oral contraceptives.
    Plu-Bureau G; Scarabin PY; Bara L; Malmejac A; Guize L; Samama M
    Thromb Res; 1993 May; 70(3):275-80. PubMed ID: 8327993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease.
    Miller GJ; Walter SJ; Stirling Y; Thompson SG; Esnouf MP; Meade TW
    Br J Haematol; 1985 Feb; 59(2):249-58. PubMed ID: 3871629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VII, cholesterol, and triglycerides. The CARDIA Study. Coronary Artery Risk Development in Young Adults Study.
    Green D; Chamberlain MA; Ruth KJ; Folsom AR; Liu K
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):51-5. PubMed ID: 9012637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy.
    Latallo ZS; Thomson JM; Poller L
    Br J Haematol; 1981 Feb; 47(2):307-18. PubMed ID: 7470395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further evaluation of an automated amidolytic factor X assay in monitoring anti-vitamin K treatment.
    van Wijk EM; Kahlé LH; Jeletich A; ten Cate JW
    Scand J Haematol; 1982 Aug; 29(2):105-14. PubMed ID: 6813960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The strong positive correlation between factor VII clotting activity using bovine thromboplastin and the activated factor VII level.
    Kario K; Matsuo T; Asada R; Sakata T; Kato H; Miyata T
    Thromb Haemost; 1995 Mar; 73(3):429-34. PubMed ID: 7667824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-linked coagulation assay. II. A sensitive assay for tissue factor and factors II, VII, and X.
    Doellgast GJ; Rothberger H
    Anal Biochem; 1986 Jan; 152(1):199-207. PubMed ID: 3006542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered factor VII activity in hemophilia.
    Miller BC; Hultin MB; Jesty J
    Blood; 1985 Apr; 65(4):845-9. PubMed ID: 3978230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays.
    Takase T; Tuddenham EG; Chand S; Goodall AH
    J Clin Pathol; 1988 Mar; 41(3):342-5. PubMed ID: 3360958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related changes in factor VII activation in healthy women.
    Scarabin PY; Van Dreden P; Bonithon-Kop C; Orssaud G; Bara L; Conard J; Samama M
    Clin Sci (Lond); 1988 Oct; 75(4):341-3. PubMed ID: 3264227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype.
    Irish AB; Green FR
    Nephrol Dial Transplant; 1998 Mar; 13(3):679-84. PubMed ID: 9550647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.